Clinical trials: Childhood Neoplasm
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Solid Tumors
A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
This is an open-label Phase 1 dose escalation study of OMP-54F28 in subjects with a solid tumor for which there is no remaining standard curative therapy.
- Trial name
- NCT01608867
- Testing
- OMP-54F28
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Advanced Cancer, Metastatic Cancer
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma
- Trial name
- NCT05557045
- Testing
- JZP815
- Where
- 15 sites in United States
- Volunteers
- 98 people
- Sponsor
- Jazz Pharmaceuticals
Nonsquamous Nonsmall Cell Neoplasm of Lung
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer
This observational study will evaluate the safety and efficacy of Tarceva (erlotinib) in routine clinical practice as second-line treatment in patients with recurrent or metastatic non-small dell lung cancer (NSCLC).
- Trial name
- TEAM (NCT01161173)
- Testing
- Erlotinib
- Where
- 36 sites in Belgium, Luxembourg
- Volunteers
- 347 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer, KRAS Activating Mutation
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced…
- Conditions
- Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer
- Trial name
- RAMP204 (NCT05375994)
- Testing
- avutometinib (VS-6766) and adagrasib
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Verastem, Inc.
Metastatic or Locally Advanced Cancer
A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)
To assess the potential for ridaforolimus to prolong the QTc interval (an effect on the electrical activity of the heart) in participants with advanced cancer. This study will be done in 2 parts.
- Trial name
- NCT00874731
- Testing
- Ridaforolimus 100 mg, Ridaforolimus 40 mg
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Liver Cancer, Secondary Liver Cancer
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
The purpose of this study is to determine whether patients treated with Radiofrequency Ablation (RFA) in conjunction with chemotherapy have a better overall survival rate than patients treated with chemotherapy alone.
- Conditions
- Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
- Trial name
- Prometheus (NCT00510627)
- Testing
- Radiofrequency Ablation (RFA), Chemotherapy
- Where
- 2 sites in United States
- Sponsor
- Boston Scientific Corporation
Metastatic Cancer, Solid Tumor
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This was the first study to test Sym023 in humans. The primary purpose of this study was to see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03489343
- Testing
- Sym023
- Where
- 4 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Symphogen A/S
Breast Cancer
A Study of LY573636-sodium in Patients With Metastatic Breast Cancer
The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636-sodium for metastatic breast cancer.
- Trial name
- NCT00992225
- Testing
- LY573636-sodium
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Metastatic Castration-Resistant Prostate Cancer
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
Provide pre-approval single-patient Expanded Access (Compassionate Use) of talazoparib for patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT05650476
- Testing
- Talazoparib
- Sponsor
- Pfizer
Solid and Hematological Malignancies
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
Subjects who previously took part in an Adaptimmune study and received genetically changed T cells (including but not limited to MAGE-A10ᶜ⁷⁹⁶T and MAGE-A4ᶜ¹º³²T) are asked to take part in this long term follow-up study.
- Trial name
- NCT03391791
- Testing
- Genetically engineered T Cell Receptors
- Where
- 3 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Adaptimmune
Leukemia, Myelodysplastic Syndromes
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00049686
- Testing
- laromustine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Metastatic Melanoma
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 combined with cisplatin.
- Trial name
- NCT01029873
- Testing
- Cisplatin, ALT-801
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Altor BioScience
Brain Neoplasms
Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors
In this study, the Visualase Thermal Therapy System will be used on metastatic brain tumors that cannot be removed by surgery. Researchers want to find out if it is possible to use this new device in subjects with 1-3 metastatic…
- Trial name
- NCT00787982
- Testing
- MRI-Guided Laser Induced Thermal Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Visualase, Inc.
Breast Cancer, Breast Neoplasms
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
The purpose of this study is to determine if AMG 386 in combination with either paclitaxel and trastuzumab or capecitabine and lapatinib is safe and well tolerated in subjects with HER2-positive locally recurrent or metastatic…
- Conditions
- Breast Cancer, Breast Neoplasms, Breast Tumors, Cancer
- Trial name
- NCT00807859
- Testing
- AMG 386 30 mg/kg, Paclitaxel and Trastuzumab, AMG 386 30 mg/kg, Capecitabine and Lapatinib, AMG 386 10 mgkg, Paclitaxel and Trastuzumab
- Where
- 23 sites in United States, Belgium and 1 more
- Volunteers
- 65 people
- Sponsor
- Amgen
Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With Systemic Therapy
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
The purpose of this study is to evaluate the efficacy and safety of nanocrystalline medroxyprogesterone acetate for improving appetite and weight gain patients with non-small cell lung cancer (NSCLC) and cachexia and…
- Trial name
- NCT06961188
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, Standard Therapy
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
HER-2 Gene Amplification, Esophagus Cancer
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
- Conditions
- HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
- Trial name
- NCT01774851
- Testing
- MM-111, Paclitaxel, Trastuzumab
- Where
- 21 sites in United States
- Volunteers
- 84 people
- Sponsor
- Merrimack Pharmaceuticals
Women's Health: Neoplasm of Breast
A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection
This is an open, multicentric, interventional, prospective, non-randomized clinical investigation. The first aim of the study is to confirm that MammoWave reaches sensitivity>75% and specificity>90% in breast cancer (BC)…
- Trial name
- NCT06291896
- Testing
- MammoWave
- Where
- 10 sites in Italy, Poland and 3 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Umbria Bioengineering Technologies
Breast Cancer
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
This post-approval study is designed to determine the performance of the FDA-approved GeneSearch™ BLN Assay when compared to the site's standard of care permanent section histological evaluation, and when compared to more…
- Trial name
- NCT00595296
- Testing
- GeneSearch™ Breast Lymph Node (BLN) Assay
- Where
- 6 sites in United States
- Volunteers
- 461 people
- Sponsor
- Janssen Diagnostics, LLC
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Beta Alethine in Treating Patients With Myeloma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006466
- Testing
- beta alethine
- Where
- 3 sites in United States
- Sponsor
- LifeTime Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.